

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 5/00	A1	(11) International Publication Number: WO 99/43785 (43) International Publication Date: 2 September 1999 (02.09.99)
(21) International Application Number: PCT/US99/04188 (22) International Filing Date: 26 February 1999 (26.02.99) (30) Priority Data: 60/076,273 27 February 1998 (27.02.98) US (71) Applicant: MEDICAL COLLEGE OF HAMPTON ROADS [US/US]; 601 Colley Avenue, Norfolk, VA 23507 (US). (72) Inventor: HODGEN, Gary, D.; 3844 Church Point Road, Virginia Beach, VA 23455 (US). (74) Agents: MEILMAN, Edward, A. et al.; Ostrolenk, Faber, Gerb & Soffen, LLP, 1180 Avenue of the Americas, New York, NY 10036 (US).		(81) Designated States: AU, CA, JP, NO, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: DERIVATION OF CELLS AND TISSUES FROM EMBRYONIC PRE-STEM CELLS FOR TRANSPLANTATION THERAPIES (57) Abstract A novel method of isolating and propagating a line of embryonic stem cells that originates from either morulae (pre-stem) or blastocyst (ICM stem cells) is disclosed for the purpose of transplanting cells, tissues or organs.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

DERIVATION OF CELLS AND TISSUES FROM
EMBRYONIC PRE-STEM CELLS FOR TRANSPLANTATION THERAPIES

Background of the Invention

5 The present invention relates to the derivation
of cells and tissues from embryonic pre-stem cells for
transplantation therapies.

Summary of the Invention

10 This invention relates to the use of dispersed
morula cells in preference to inner cell mass (ICM) from
blastocysts. The morula stage is the last pre-embryonic
stage without expression of any differentiation, making
these cells (pre-stem cells) all progenitors of embryonic
stem cells (ESCs) later present in blastocysts.
15 Conversely, the ICM from the blastocyst is already
differentiated from trophoblastic cells, which are by then
destined to become part of the placenta.

20 This invention also relates to the use of
chimeric introductions into pre-stem cell cultures and stem
cell propagations in culture. That is, "teacher-cells" or
spent media from them, that derived from other sources
(e.g. adults, cord blood, fetal tissues, etc.) will "teach"
undifferentiated pre-stem cells how to convert to our
sought-after therapeutic cell population both more rapidly
and more preferentially.

25 This invention also relates to the identification
and use of certain early markers of stem cell

- 2 -

differentiation, such as Fe⁺⁺ sequestration, hemoglobin accumulation, myeloid fibers, insulin synthesis, dopamine loading, etc.

5 Other features and advantages of the present invention will become apparent from the following description of the invention.

Detailed Description of the Invention

10 The present invention provides for a method of isolating and propagating a line of embryonic stem cells that originates from either morulae (pre-stem) or blastocyst (ICM stem cells). Therefore, Morula stage, undifferentiated pre-stem cells will be used as progenitors of stem cell populations. The propagated line of embryonic stem cells are then used for the purpose of transplanting
15 cells, tissues or organs.

The propagation of stem cells can be initiated by formation of chimeric inner cell mass cells. Chimeric ICMS will be developed from blastocysts. From such ICMS, superior stem cell cultures are derived. Preferably, the
20 formation of chimeric inner cell mass cells comprises nuclear transplantation, mitochondrial substitution, or cytoplasmic depletion.

25 Preferably, at least one regulatory factor is used to propagate the line of embryonic stem cells. More preferably, the regulatory factor is derived from "Teacher cells" or "Teacher cells'" spent culture medium. "Teacher cells" will be introduced into less differentiated pre-stem or early stage stem cells to accelerate propagation of target stem cells. Alternatively, spent media from

- 3 -

"teacher cells" can be used to accelerate the propagation of the target stem cells.

5 In a preferred embodiment, the embryonic stem cells are cultured in a medium in the presence of at least one agent or cytokine in order to differentiate into target specific cells or tissues. Preferably, the agent or cytokine is selected from the group consisting of IL-1, TNF- α , IL-6, PTH, PDGF, PGE₂, cAMP, estrogens, anti-estrogens, progestins, anti-progestins, cortisol, GH, 10 androgens, I₃/T₃, VEGF and cyclosporin. Also preferably, the concentration of the agent or cytokine in culture medium is from about 1.0 pg/ml to about 10.0 ng/ml.

15 In another preferred embodiment, the target specific cells are selected from the group consisting of nerve cells, bone cells, immune cells, and pancreatic beta cells.

20 Techniques and parameters for the use of a broad spectrum of early stage metabolic markers are developed. Some such markers are, for example: Fe++ sequestration, Hg accumulation, myeloid fibers, nerve growth factor, apoptotic factors, insulin synthesis, dopamine loading, hemoglobin loading, etc. Additionally, other early markers of embryonic stem cells can be identified.

25 Specific techniques are developed to demonstrate the foregoing. In one embodiment of the invention, embryonic stem (ES) cells are derived from either morula or blastocyst stage embryos by placing cells on fibroblast feeder layers. The colonies are evaluated for differentiation state using accepted markers. Further

- 4 -

5 evaluation is done by injecting ES cells into surrogate embryos to produce chimeras and evaluating the contribution of the ES cells to the adult tissues. Finally, ideal colonies of ES cells are used as nuclear donors for nuclear transplantation.

10 Clonal properties of the propagated stem cells can be achieved by adding apoptotic factors, cytokines or other agents to the culture medium to eliminate contaminating members of the stem cells that did not properly differentiate. Preferably, the cytokines or agents are selected from the group consisting of IL-1, TNF- α , IL-6, PTH, PDGF, PGE₂, cAMP, estrogens, anti-estrogens, progestins, anti-progestins, cortisol, GH, androgens, I₃/T₃, VGEF and cyclosporin.

15 Alternatively, the propagation of the line of embryonic stem cells is done *in vivo* by transplanting "Teacher cells" into an area sufficiently close to the embryonic stem cells to allow for at least one regulatory factor made by the teacher cells to contact the embryonic cells.
20

The presence or absence of different concentrations of calcium can be used to regulate the propagation of the line of embryonic stem cells.

25 Preferably, the propagated line of embryonic stem cells is grown in a three dimensional manner before being used for transplantation.

This invention will allow for the efficient, safe and commercially viable derivation of cells and tissues

- 5 -

from embryonic pre-stem cells for transplantation therapies. Specifically, growing-out of human blastocysts at a rate greater than 50% from the 2-cell stage of the pre-embryo should be achieved. Also, efficient harvesting of either morula stage pre-stem cells and/or stem cells isolated from the inner cell mass of blastocysts should be achieved. These embryonic pre-stem and stem cell populations should preferably remain viable in culture for more than one week.

10 Example 1

Clonal production of stem cells will be undertaken. These clones will respond to the ambient levels of glucose in their milieu, and in turn, insulin-dependent diabetes would be treated by transplanting these stem cell lines to served by a peripheral blood supply. the insulin secretory cells must accomplish renewal y propagation through mitogenic proliferation.

Example 2

Pluripotent stem cells will be isolated and directed to differentiate into hemopoietic destinies. Therefore, tissues derived from the blood cell group or beta cells of the immune response system will be replaced in deficient patients suffering from conditions such as HIV infection, post-chemotherapy, or irradiation depletion. Culture condition in vitro will direct the rate and degree of differentiation manifested by these pluripotent stem cells, such as the presence of "teacher cells" or certain additives to the media, e.g. cytokines.

Example 3

- 6 -

5 The inherent capabilities of stem cells will be
modified by formation of chimeric cell lines that
incorporate "hybrid" metabolic functions that when
transplanted will provide the transplant recipient with
10 long-term relief from organ/tissue deficiencies. For
instance, the production of dopamine *in situ* can modify
neurological treatments for patients manifesting muscular
rigidity and loss of motor control in disease states such
as Parkinson's disease. Unlike pharmaceutical therapeutics
15 which are partially effective temporarily, transplantation
of chimeric stem cells that regulate the production
dopamine and serotonergic factors will offer these patients
superior outcomes.

15 The invention has been described in terms of
preferred embodiments thereof, but is more broadly
applicable as will be understood by those skilled in the
art. the scope of the invention is therefore limited only
by the following claims.

- 7 -

What is claimed is:

1. A method of isolating and propagating a line of embryonic stem cells that originates from either morulae (pre-stem) or blastocyst (ICM stem cells).
- 5 2. The method of claim 1, wherein the propagated line of embryonic stem cells are used for the purpose of transplanting cells, tissues or organs.
3. The method of claim 1, wherein at least one regulatory factor is used to propagate the line of
10 embryonic stem cells.
4. The method of claim 3, wherein the regulatory factor is derived from teacher cells or teacher cells' spent culture medium.
5. The method of claim 3, wherein the
15 propagation is initiated by the formation of chimeric inner cell mass cells.
6. The method of claim 5, wherein the formation of chimeric inner cell mass cells comprises nuclear
20 transplantation, mitochondrial substitution, or cytoplasmic depletion.
7. The method of claim 1, wherein the embryonic stem cells are cultured in a medium in the presence of at least one agent or cytokine in order to differentiate into specific cells or tissues.
- 25 8. The method of claim 7, wherein the agent or cytokine is selected from the group consisting of IL-1,

- 8 -

TNF- α , IL-6, PTH, PDGF, PGE₂, cAMP, estrogens, anti-estrogens, progestins, anti-progestins, cortisol, GH, androgens, I₃/T₃, VGEF and cyclosporin.

5 9. The method of claim 7, wherein the concentration of the agent or cytokine in culture medium is from about 1.0 pg/ml to about 10.0 ng/ml.

10 10. The method of claim 7, wherein the specific cells are selected from the group consisting of nerve cells, bone cells, immune cells, and pancreatic beta cells.

15 11. The method of claim 7, wherein the embryonic stem cell differentiation is identified by at least one marker substance that accumulates in culture medium.

20 12. The method of claim 11, wherein the marker substance is selected from the group consisting of an iron sequestering substance, insulin, dopamine, myeloid fibers, and hemoglobin.

25 13. The method of claim 5, wherein the formation of chimeric inner cell mass cells enhances the proficiency of stem cells to both replicate and perform metabolic functions that restore essential body function.

 14. The method of claim 1, wherein clonal properties of the propagated stem cells is achieved by adding apoptotic factors to the culture medium to eliminate contaminating members of the stem cells that did not properly differentiate.

- 9 -

5 15. The method of claim 1, wherein clonal properties of the propagated stem cells is achieved by adding at least one agent or cytokine to the culture medium to eliminate contaminating members of the stem cells that did not properly differentiate, wherein the agent or cytokine is selected from the group consisting of IL-1, TNF- α , IL-6, PTH, PDGF, PGE₂, cAMP, estrogens, anti-estrogens, progestins, anti-progestins, cortisol, GH, androgens, I₃/T₃, VGEF and cyclosporin.

16. The method of claim 1, wherein the propagation of the line of embryonic stem cells is done *in vivo* by transplanting teacher cells into an area sufficiently close to the embryonic stem cells to allow for at least one regulatory factor made by the teacher cells to contact the embryonic cells.

17. The method of claim 1, wherein the presence or absence of different concentrations of calcium is used to regulate the propagation of the line of embryonic stem cells.

18. The method of claim 1, wherein the propagated line of embryonic stem cells is grown in a three dimensional manner before being transplanted.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/04188

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :C12N 5/00

US CL :435/325

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/325

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, NPL

search terms: embryonic stem cells, morulae, blastocyst, inner cell mass

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,453,366 A (SIMS et al.) 26 September 1995, see entire document.	1-18
Y	STERLCHENKO, N. Bovine Pluripotent Stem Cells. Theriogenology. 1996, Vol. 45, pages 131-140, see entire document.	1-18
Y	OKABE et al. Development of Neuronal Precursor Cells and Functional Postmitotic Neurons from Embryonic Stem Cells In Vitro. Mechanisms of Development. 1996, Vol. 59, pages 89-102, see entire document.	1-18
Y	SHIM et al. Isolation of Pluripotent Stem Cells from Cultured Porcine Primordial Germ Cells. Theriogenology. 01 January 1997, Vol. 47, No. 1, page 245, see entire document.	1-18

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 10 MAY 1999	Date of mailing of the international search report 27 MAY 1999
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer <i>D. Laurence For</i> JILL D. MARTIN Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/04188

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	DINSMORE et al. Embryonic Stem Cells Differentiated In Vitro as a Novel Source of Cells for Transplantation. Cell Transplantation. 1996, Vol. 5, No. 2, pages 131-143, see entire document.	1-18
Y	SOTOMARU et al. A Comparative Investigation on the Potency of Cells from the Inner Cell Mass and Trophectoderm of Mouse Blastocysts to Produce Chimeras. Theriogenology. 1997, Vol. 48, pages 977-984, see entire document.	1-18
Y	UCHIDA et al. Effects of Feeder Cells and Growth Factors on the Proliferation of Mouse Primordial Germ Cells. Theriogenology. 1995, Vol. 44, pages 9-16, see entire document.	1-18